Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
April 29, 2022 at 10:30 am EDT
Share
Kunming Longjin Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 698.35 million compared to CNY 253.71 million a year ago. Revenue was CNY 702.52 million compared to CNY 254.03 million a year ago. Net income was CNY 3.09 million compared to CNY 11.81 million a year ago. Basic earnings per share from continuing operations was CNY 0.0077 compared to CNY 0.0295 a year ago. Diluted earnings per share from continuing operations was CNY 0.0077 compared to CNY 0.0295 a year ago.
Kunming Longjin Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and sales of natural botanical and chemical lyophilized powder injection. The Company's products cover traditional Chinese medicine, biochemical medicine and chemical medicine, which including cardio-cerebral vascular medicine, digestive system medicine, immune system medicine, vitamins, mineral enteral and parenteral nutrition medicines. The main products of which is breviscapine injection. The Company conducts its businesses primarily within the domestic market.
KUNMING LONGJIN PHARMACEUTICAL CO., LTD. 
